术前乳腺MRI上与恶性指数癌肿块相连的非肿块强化:影像-病理相关性
本研究回顾性分析了58例新诊断乳腺癌患者术前MRI上直接邻近活检证实恶性肿块(指数肿块)的非肿块强化(NME),发现64%(37/58)的NME病理为恶性,其中43%(16/37)为导管原位癌、57%(21/37)为浸润性癌;指数癌Ki-67指数<20%时NME更可能为恶性(P=0.04);MRI测量的可疑强化范围高估了组织学真实病变范围(P<0.001),而乳腺X线钙化范围与组织学真实范围无差异证据(P=0.27)。
要点
- 术前MRI上邻近恶性肿块的NME在64%(37/58)患者中为恶性,报告时应描述其范围。
- 指数癌Ki-67<20%时NME更可能为恶性(P=0.04)。
- MRI测量的可疑强化范围高估组织学真实范围(P<0.001),报告范围需谨慎。
核心结论
- 术前MRI上肿块相关NME在新诊断乳腺癌患者中多数为恶性,且MRI测量的可疑强化范围高估了组织学评估的真实病变范围。
研究设计与样本
- 回顾性研究,纳入2016年7月1日至2019年9月30日期间因新诊断乳腺癌评估病变范围而行乳腺MRI和乳腺X线检查的患者,纳入标准限有指数肿块且NME直接从肿块边缘延伸者,共58例(平均年龄58岁±12[SD],均为女性)。
关键影像表现/征象
- 肿块相关NME的恶性病理结果见于64%(37/58)患者,其中43%(16/37)为导管原位癌、57%(21/37)为浸润性癌。
- 与乳腺X线所见钙化相对应的肿块相关NME,其钙化存在与恶性病理无显著关联(P=0.19)。
- MRI测量的可疑强化范围超过组织学评估的真实病变范围(P<0.001)。
- 乳腺X线测量的钙化范围与组织学评估的真实病变范围无差异证据(P=0.27)。
诊断标准与关键数值
- NME恶性率:64%(37/58);其中导管原位癌43%(16/37)、浸润性癌57%(21/37)。
- 指数癌Ki-67<20%时NME更可能为恶性(P=0.04)。
- MRI可疑强化范围与组织学真实范围比较:P<0.001(MRI高估)。
- 乳腺X线钙化范围与组织学真实范围比较:P=0.27(无差异证据)。
临床应用与阅片要点
- 术前MRI发现与恶性指数肿块相连的NME时,应描述其范围,因其多数为恶性(64%,37/58)。
- 报告MRI可疑强化范围时需注意其可能高估组织学真实病变范围(P<0.001)。
- 乳腺X线钙化范围与组织学真实范围无差异证据(P=0.27),可结合钙化范围辅助评估。
- 指数癌Ki-67<20%时NME更可能为恶性(P=0.04),可与病理信息结合解读。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine the pathologic features of nonmass enhancement (NME) directly adjacent to biopsy-proven malignant masses (index masses) at preoperative MRI and determine imaging characteristics that are associated with a malignant pathologic condition. Materials and Methods This retrospective study involved the review of breast MRI and mammography examinations performed for evaluating disease extent in patients newly diagnosed with breast cancer from July 1, 2016, to September 30, 2019. Inclusion criteria were limited to patients with an index mass and the presence of NME extending directly from the mass margins. Wilcoxon rank sum test, Fisher exact test, and χ2 test were used to analyze cancer, patient, and imaging characteristics associated with the NME diagnosis. Results Fifty-eight patients (mean age, 58 years ± 12 [SD]; all women) were included. Malignant pathologic findings for mass-associated NME occurred in 64% (37 of 58) of patients, 43% (16 of 37) with ductal carcinoma in situ and 57% (21 of 37) with invasive carcinoma. NME was more likely to be malignant when associated with an index cancer that had a low Ki-67 index (<20%) (P = .04). The presence of calcifications at mammography correlating with mass-associated NME was not significantly associated with malignant pathologic conditions (P = .19). The span of suspicious enhancement measured at MRI overestimated the true span of disease at histologic evaluation (P < .001), while there was no evidence of a difference between span of calcifications at mammography and true span of disease at histologic evaluation (P = .27). Conclusion Mass-associated NME at preoperative MRI was malignant in most patients with newly diagnosed breast cancer. The span of suspicious enhancement measured at MRI overestimated the true span of disease found at histologic evaluation. Keywords: Breast, Mammography © RSNA, 2024 See also the commentary by Newell in this issue.
引用
- Nguyen DL, Lotfalla M, Cimino-Mathews A, et al. Radiologic-Pathologic Correlation of Nonmass Enhancement Contiguous with Malignant Index Breast Cancer Masses at Preoperative Breast MRI. Radiol Imaging Cancer. 2024. PMID: 38305717. doi:10.1148/rycan.230060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。